Skip to content

Study of Yisui moxa cone moxibustion on the regulation of brain function and brain metabolism network in patients with subjective cognitive decline.

Study of Yisui moxa cone moxibustion on the regulation of brain function and brain metabolism network in patients with subjective cognitive decline.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006078
Enrollment
Unknown
Registered
2022-06-07
Start date
2022-06-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

subjective cognitive decline

Interventions

Healthy group control:no
control group:no

Sponsors

First Affiliated Hospital, Guangxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with MCI diagnostic criteria consistent;2.55 to 70 years old, right-handed3The main complaint is about the decline of memory;4Chinese native speaker, education level of more than 6 years, MMSE: junior high school and above > 27 points5the ability of daily life unaffected or slight affected6No visual, auditory or intellectual impairment, no language barrier, can answer and fill in the questionnaire smoothly;7.Without acupuncture and moxibustion treatment for nearly 1 month,No psychotropic drugs affecting cognition were taken before and during treatment8All subjects obtained informed consent, voluntarily cooperated and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) MCI, AD prodrome, dementia;(2) Other neurological diseases that can lead to cognitive decline, except for suspected early AD, such as Parkinson's disease, vascular-derived dementia, and brain tumors;(3) Patients with severe systemic diseases such as heart, liver and renal insufficiency and other systemic diseases that can cause cognitive decline, such as thyroid dysfunction, anemia, hepatic encephalopathy, renal encephalopathy, etc.;(4) Abnormal brain structure, such as intellectual development disorder, brain infection, cerebral infarction, cerebral hemorrhage and a history of severe head trauma or other diseases involving the central nervous system, thus affecting the neuropsychological scale assessment;(5) A history of depression, anxiety, bidirectional disorder, schizophrenia and other mental disorders;(6) History of substance or substance abuse / addiction in the past 1 year;(7) Those who have received cognitive function-related treatment in the past 1 month;(8) Severe hearing, visual impairment and aphasia who are unable to evaluate or complete the test;, (9) those with metal residues in the body and unable to perform MRI examination;(10) Failure to complete the project due to any other uncertain situation.

Design outcomes

Primary

MeasureTime frame
Diffusion Tensor Imaging;Magnetic Resonance Spectroscopy;resting-state fMRI;Apparent Diffusion Coefficient;scales;Serum oestradiol, testosterone, and progesterone levels;

Countries

China

Contacts

Public ContactLihua zhao
zhaolh67@163.com+86 13006913108

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026